Advertisement

Topics

BioSyent to Present at Upcoming Investor Conferences

20:00 EDT 24 Apr 2018 | Globe Newswire

TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that it will be presenting at the following upcoming investor conferences:

May 2, 2018 - Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto, Toronto, Ontario.  Mr. René Goehrum, BioSyent’s President and CEO, will present to investors an overview of BioSyent’s business and corporate activities on Wednesday, May 2nd at 2:30 p.m. ET.  Mr. Goehrum and Mr. Peter Weiler, BioSyent’s Vice President of Business Development, will also be available to meet with investors on a one-on-one basis during the conference on May 2nd and 3rd. These one-on-one meetings can be requested by attendees through the online conference portal: https://www.bloomburton.com/bloom-burton-co-healthcare-investor-conference/.

May 10, 2018 – East Coast IDEAS Investor Conference at the Boston Park Plaza, Boston, Massachusetts.  Mr. Goehrum will present to investors on Thursday, May 10th at 9:50 a.m. ET.  The audio portion of the presentation will be webcast live and will be available for playback for 30 days following the presentation at the following link: http://www.wsw.com/webcast/threepa25/bioyf.  Mr. Goehrum will also be available for one-on-one meetings during the day on May 10th.  Interested investors can request meetings with Mr. Goehrum through the online conference platform: https://www.meetmax.com/sched/event_48311/entity_login.html?attendee_role_id=COMPANY.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,509,095 common shares issued and outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "BioSyent to Present at Upcoming Investor Conferences"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...